Adjuvant histamine in cancer immunotherapy

Seminars in Cancer Biology

Volumn 10, Issue 1, 2000, Pages 29-39

  Hellstrand, Kristoffer ^a   Hansson, Markus ^a   Hermodsson, Svante ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Histamine; Immunotherapy; Macrophages; NK cells; T cells

Indexed keywords

ALPHA INTERFERON; CIMETIDINE; CYPROHEPTADINE; CYTOKINE; DIMAPRIT; HISTAMINE; INTERLEUKIN 2; PROSTAGLANDIN; RANITIDINE; REACTIVE OXYGEN METABOLITE;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER INHIBITION; CLINICAL TRIAL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG POTENTIATION; EXPERIMENTAL NEOPLASM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INHIBITION KINETICS; LYMPHOCYTE ACTIVATION; MACROPHAGE; MELANOMA; NATURAL KILLER CELL; NONHUMAN; OXIDATION; REMISSION; REVIEW; T LYMPHOCYTE;

EID: 0034122236     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1006/scbi.2000.0305     Document Type: Article

References (105)

1. Eccles S A, Alexander P. Macrophage content of tumours in relation to metastatic spread and host immune reaction. Nature. 250:1974;667-669.
2. Alexander P, Eccles S A, Gauci C L. The significance of macrophages in human and experimental tumors. Ann N Y Acad Sci. 276:1976;124-133.
3. Kirchner H, Chused T M, Herberman R B, Holden H T, Lavrin D H. Evidence of suppressor cell activity in spleens of mice bearing primary tumors induced by Moloney sarcoma virus. J Exp Med. 139:1974;1473-1487.
4. Glaser M, Kirchner H, Herberman R B. Inhibition of in vitro lymphoproliferative responses to tumor-associated antigens by suppressor cells from rats bearing progressively growing Gross leukemia virus-induced tumors. Int J Cancer. 16:1975;384-393.
5. Pope B L, Whitney R B, Levy J G, Kilburn D G. Suppressor cells in the spleens of tumor-bearing mice: enrichment by centrifugation on hypaque-ficoll and characterization of the suppressor population. J Immunol. 116:1976;1342-1346.
6. Yamagishi H, Pellis N R, Mokyr M B, Kahan B D. Specific and non-specific immunologic mechanisms of tumor growth facilitation. Cancer. 45:1980;2929-2933.
7. Yamagishi H, Oka T, Hashimoto I, Pellis N R, Kahan B D. The role of the spleen in tumor bearing host: II. The influence of splenectomy in mice. Jpn J Surg. 14:1984;72-77.
8. Yamagishi H, Oka T, Hashimoto I, Pellis N R, Kahan B D. The role of the spleen in tumor bearing host: I. Characterization of spleen cells in tumor-bearing mice. Jpn J Surg. 14:1984;61-71.
9. Allen C, Hogg N. Monocytes and other infiltrating cells in human colorectal tumours identified by monoclonal antibodies. Immunology. 55:1985;289-299.
10. Leek R D, Lewis C E, Whitehouse R, Greenall M, Clarke J, Harris A L. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res. 56:1996;4625-4629.
11. Brocker E B, Zwadlo G, Suter L, Brune M, Sorg C. Infiltration of primary and metastatic melanomas with macrophages of the 25F9-positive phenotype. Cancer Immunol Immunother. 25:1987;81-86.
12. Brocker E B, Zwadlo G, Holzmann B, Macher E, Sorg C. Inflammatory cell infiltrates in human melanoma at different stages of tumor progression. Int J Cancer. 41:1988;562-567.
13. Heidl G, Davaris P, Zwadlo G, Jagoda M S, Duchting S, Bierhoff E, Gruter T, Krieg V, Sorg C. Association of macrophages detected with monoclonal antibody 25 F 9 with progression and pathobiological classification of gastric carcinoma. J Cancer Res Clin Oncol. 113:1987;567-572.
14. Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol. 3:1992;65-71.
15. Ono M, Torisu H, Fukushi J, Nishie A, Kuwano M. Biological implications of macrophage infiltration in human tumor angiogenesis. Cancer Chemother Pharmacol. 43:1999;S69-71.
16. Herberman R B, Holden H T, Djeu J Y, Jerrells T R, Varesio L, Tagliabue A, White S L, Oehler J R, Dean J H. Macrophages as regulators of immune responses against tumors. Adv Exp Med Biol. 1979;361-379.
17. Elgert K D, Alleva D G, Mullins D W. Tumor-induced immune dysfunction: the macrophage connection. J Leukocyte Biol. 64:1998;275-290.
18. Kiessling R, Kono K, Petersson M, Wasserman K. Immunosuppression in human tumor-host interaction: role of cytokines and alterations in signal-transducing molecules. Springer Semin Immunopathol. 18:1996;227-242.
19. Dohlsten M. Synergistic action of gamma interferon and catalase to reverse the suppressive effect of peritoneal macrophages on concanavalin A-induced lymphocyte proliferation. Scand J Immunol. 24:1986;49-58.
20. Linden O, Dohlsten M, Boketoft A, Hedlund G, Sjogren H O. Catalase and lipopolysaccharide enhance proliferation in the rat mixed lymphocyte reaction. Scand J Immunol. 26:1987;223-228.
21. Seaman W E, Gindhart T D, Blackman M A, Dalal B, Talal N, Werb Z. Natural killing of tumor cells by human peripheral blood cells. Suppression of killing in vitro by tumor-promoting phorbol diesters. J Clin Invest. 67:1981;1324-1333.
22. Seaman W E, Gindhart T D, Blackman M A, Dalal B, Talal N, Werb Z. Suppression of natural killing in vitro by monocytes and polymorphonuclear leukocytes: requirement for reactive metabolites of oxygen. J Clin Invest. 69:1982;876-888.
23. Hellstrand K, Hermodsson S. Histamine H2-receptor-mediated regulation of human natural killer cell activity. J Immunol. 137:1986;656-660.
24. Hellstrand K, Hermodsson S. Role of serotonin in the regulation of human natural killer cell cytotoxicity. J Immunol. 139:1987;869-875.
25. Hellstrand K, Hermodsson S. Synergistic activation of human natural killer cell cytotoxicity by histamine and interleukin-2. Int Arch Allergy Appl Immunol. 92:1990;379-389.
26. Mizoguchi H, O'Shea J J, Longo D L, Loeffler C M, McVicar D W, Ochoa A C. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science. 258:1992;1795-1798.
27. Aoe T, Okamoto Y, Saito T. Activated macrophages induce structural abnormalities of the T cell receptor-CD3 complex. J Exp Med. 181:1995;1881-1886.
28. Otsuji M, Kimura Y, Aoe T, Okamoto Y, Saito T. Oxidative stress by tumor-derived macrophages suppresses the expression of CD3 zeta chain of T-cell receptor complex and antigen-specific T-cell responses. Proc Natl Acad Sci U S A. 93:1996;13119-13124.
29. Finke J H, Zea A H, Stanley J, Longo D L, Mizoguchi H, Tubbs R R, Wiltrout R H, O'Shea J J, Kudoh S, Klein E et al. Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma. Cancer Res. 53:1993;5613-5616.
30. Nakagomi H, Petersson M, Magnusson I, Juhlin C, Matsuda M, Mellstedt H, Taupin J L, Vivier E, Anderson P, Kiessling R. Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res. 53:1993;5610-5612.
31. Matsuda M, Petersson M, Lenkei R, Taupin J L, Magnusson I, Mellstedt H, Anderson P, Kiessling R. Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumor-infiltrating, gut mucosal and peripheral lymphocytes: correlation with the stage of the disease. Int J Cancer. 61:1995;765-772.
32. Zea A H, Curti B D, Longo D L, Alvord W G, Strobl S L, Mizoguchi H, Creekmore S P, O'Shea J J, Powers G C, Urba W J, et al. Alterations in T cell receptor and signal transduction molecules in melanoma patients. Clin Cancer Res. 1:1995;1327-1335.
33. Kono K, Ressing M E, Brandt R M, Melief C J, Potkul R K, Andersson B, Petersson M, Kast W M, Kiessling R. Decreased expression of signal-transducing zeta chain in peripheral T cells and natural killer cells in patients with cervical cancer. Clin Cancer Res. 2:1996;1825-1828.
34. Kono K, Salazar-Onfray F, Petersson M, Hansson J, Masucci G, Wasserman K, Nakazawa T, Anderson P, Kiessling R. Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell- and natural killer cell-mediated cytotoxicity. Eur J Immunol. 26:1996;1308-1313.
35. Rabinowich H, Banks M, Reichert T E, Logan T F, Kirkwood J M, Whiteside T L. Expression and activity of signaling molecules in T lymphocytes obtained from patients with metastatic melanoma before and after interleukin 2 therapy. Clin Cancer Res. 2:1996;1263-1274.
36. Buggins A G, Hirst W J, Pagliuca A, Mufti G J. Variable expression of CD3-zeta and associated protein tyrosine kinases in lymphocytes from patients with myeloid malignancies. Br J Haematol. 100:1998;784-792.
37. Healy C G, Simons J W, Carducci M A, DeWeese T L, Bartkowski M, Tong K P, Bolton W E. Impaired expression and function of signal-transducing zeta chains in peripheral T cells and natural killer cells in patients with prostate cancer. Cytometry. 32:1998;109-119.
38. Kuss I, Saito T, Johnson J T, Whiteside T L. Clinical significance of decreased zeta chain expression in peripheral blood lymphocytes of patients with head and neck cancer. Clin Cancer Res. 5:1999;329-334.
39. Horiguchi S, Petersson M, Nakazawa T, Kanda M, Zea A H, Ochoa A C, Kiessling R. Primary chemically induced tumors induce profound immunosuppression concomitant with apoptosis and alterations in signal transduction in T cells and NK cells. Cancer Res. 59:1999;2950-2956.
40. Whiteside T L. Signaling defects in T lymphocytes of patients with malignancy. Cancer Immunol Immunother. 48:1999;346-352.
41. Hellstrand K, Asea A, Dahlgren C, Hermodsson S. Histaminergic regulation of NK cells. Role of monocyte-derived reactive oxygen metabolites. J Immunol. 153:1994;4940-4947.
42. Hansson M, Asea A, Ersson U, Hermodsson S, Hellstrand K. Induction of apoptosis in NK cells by monocyte-derived reactive oxygen metabolites. J Immunol. 156:1996;42-47.
43. Reichert T E, Day R, Wagner E M, Whiteside T L. Absent or low expression of the zeta chain in T cells at the tumor site correlates with poor survival in patients with oral carcinoma. Cancer Res. 58:1998;5344-5347.
44. Levey D L, Srivastava P K. Alterations in T cells of cancer-bearers: whence specificity? Immunol Today. 17:1996;365-368.
45. Trinchieri G. Biology of natural killer cells. Adv Immunol. 47:1989;187-376.
46. Hellstrand K, Hermodsson S. Cell-to-cell mediated inhibition of natural killer cell proliferation by monocytes and its regulation by histamine H2-receptors. Scand J Immunol. 34:1991;741-752.
47. Hansson M, Asea A, Hermodsson S, Hellstrand K. Histaminergic regulation of NK-cells: protection against monocyte-induced apoptosis. Scand J Immunol. 44:1996;193-196.
48. Hansson M, Hermodsson S, Brune M, Mellqvist U, Naredi P, Betten A, Gehlsen K, Hellstrand K. Histamine protects T cells and natural killer cells against oxidative stress. J Interferon Cytokine Res. 19:1999;1135-1144.
49. Bottazzi B, Walter S, Govoni D, Colotta F, Mantovani A. Monocyte chemotactic cytokine gene transfer modulates macrophage infiltration, growth, and susceptibility to IL-2 therapy of a murine melanoma. J Immunol. 148:1992;1280-1285.
50. Yim C Y, Hibbs J B, Jr., McGregor J R, Galinsky R E, Samlowski W E. Use of N-acetyl cysteine to increase intracellular glutathione during the induction of antitumor responses by IL-2. J Immunol. 152:1994;5796-5805.
51. Slater A F, Stefan C, Nobel I, van den Dobbelsteen D J, Orrenius S. Signalling mechanisms and oxidative stress in apoptosis. Toxicol Lett. 82-83:1995;149-153.
52. Brune M, Hellstrand K. Remission maintenance therapy with histamine and interleukin-2 in acute myelogenous leukaemia. Br J Haematol. 92:1996;620-626.
53. Asea A, Hansson M, Czerkinsky C, Houze T, Hermodsson S, Strannegard O, Hellstrand K. Histaminergic regulation of interferon-gamma (IFN-gamma) production by human natural killer (NK) cells. Clin Exp Immunol. 105:1996;376-382.
54. Dohlsten M. Suppressive Effects of Histamine on T Cell Activation. 1988;Lund university, Lund. p. 1-87.
55. Dohlsten M, Sjogren H O, Carlsson R. Histamine inhibits interferon-gamma production via suppression of interleukin 2 synthesis. Cell Immunol. 101:1986;493-501.
56. Dohlsten M, Sjogren H O, Carlsson R. Histamine acts directly on human T cells to inhibit interleukin-2 and interferon-gamma production. Cell Immunol. 109:1987;65-74.
57. Dohlsten M, Hedlund G, Sjogren H O, Carlsson R. Inhibitory effects of histamine on interleukin 2 and gamma interferon production of different human T helper cell subsets. Scand J Immunol. 28:1988;727-733.
58. Elenkov I J, Webster E, Papanicolaou D A, Fleisher T A, Chrousos G P, Wilder R L. Histamine potently suppresses human IL-12 and stimulates IL-10 production via H2 receptors. J Immunol. 161:1998;2586-2593.
59. van der Pouw Kraan T C, Snijders A, Boeije L C, de Groot E R, Alewijnse A E, Leurs R, Aarden L A. Histamine inhibits the production of interleukin-12 through interaction with H2 receptors. J Clin Invest. 102:1998;1866-1873.
60. Bury T B, Corhay J L, Radermecker M F. Histamine-induced inhibition of neutrophil chemotaxis and T-lymphocyte proliferation in man. Allergy. 47:1992;624-629.
61. Lynch N R, Salomon J C. Passive local anaphylaxis: demonstration of antitumor activity and complementation of intratumor BCG. J Natl Cancer Inst. 58:1977;1093-1098.
62. Burtin C, Scheinmann P, Salomon J C, Lespinats G, Canu P. Decrease in tumour growth by injections of histamine or serotonin in fibrosarcoma-bearing mice: influence of H1 and H2 histamine receptors. Br J Cancer. 45:1982;54-60.
63. ′-nitro- N -nitrosoguanidine. J Natl Cancer Inst. 76:1986;277-281.
64. dellaRovere F, Broccio G, Granata A, Fimiani V. In vivo experimental demonstration that hyperhistaminism counteracts tumor growth. Oncol Reports. 1:1994;175-177.
65. Cricco G, Davido C, Bergoc R, Rivera E. Inhibition of tumor growth induced by histamine - in vivo and in vitro studies. Agents Action. 38:1993;C175-C177.
66. Hellstrand K, Asea A, Hermodsson S. Role of histamine in natural killer cell-mediated resistance against tumor cells. J Immunol. 145:1990;4365-4370.
67. Suonio E, Tuomisto L, Alhava E. Effects of histamine, H1, H2 and Hic receptor antagonists and alpha-fluoromethylhistidine on the growth of human colorectal cancer in the subrenal capsule assay. Agents Actions. 41:1994;Spec No:C118-120.
68. Rizell M, Lindner P, Hellstrand K, Naredi P. Effect of histamine dihydrochloride on tumor growth rate and tumor blood flow. Int J Microcirc. 17:1997;98-105.
69. Asea A, Hermodsson S, Hellstrand K. Histaminergic regulation of natural killer cell-mediated clearance of tumour cells in mice. Scand J Immunol. 43:1996;9-15.
70. Adams W J, Lawson J A, Morris D L. Cimetidine inhibits in vivo growth of human colon cancer and reverses histamine stimulated in vitro and in vivo growth. Gut. 35:1994;1632-1636.
71. Gifford R R, Voss B V, Ferguson R M. Cimetidine protection against lethal tumor challenge in mice. Surgery. 90:1981;344-351.
72. Gorczynski R M, Kennedy M, Ciampi A. Cimetidine reverses tumor growth enhancement of plasmacytoma tumors in mice demonstrating conditioned immunosuppression. J Immunol. 134:1985;4261-4266.
73. Caignard A, Martin M, Reisser D, Thomas B, Martin F. Effects of cimetidine and indomethacin on the growth of dimethylhydrazine-induced or transplanted intestinal cancers in the rat. Br J Cancer. 50:1984;661-665.
74. Anderson L M, Giner-Sorolla A, Haller I M, Budinger J M. Effects of cimetidine, nitrite, cimetidine plus nitrite, and nitrosocimetidine on tumors in mice following transplacental plus chronic lifetime exposure. Cancer Res. 45:1985;3561-3566.
75. Mandanas R, Schultz S, Scullin D, Einhorn L H. Phase II trial of cimetidine in metastatic melanoma. A Hoosier Oncology Group trial. Am J Clin Oncol. 14:1991;397-399.
76. Creagan E T, Ahmann D L, Green S J, Long H J, Frytak S, Itri L M. Phase II study of recombinant leukocyte A interferon (IFN-rA) plus cimetidine in disseminated malignant melanoma. J Clin Oncol. 3:1985;977-981.
77. Links M, Clingan P R, Phadke K, O'Baugh J, Legge J, Adams W J, Ross W B, Morris D L. A randomized trial of cimetidine with 5-fluorouracil and folinic acid in metastatic colorectal cancer. Eur J Surg Oncol. 21:1995;523-525.
78. Tonnesen H, Knigge U, Bulow S, Damm P, Fischerman K, Hesselfeldt P, Hjortrup A, Pedersen I K, Pedersen V M, Siemssen O J, et al. Effect of cimetidine on survival after gastric cancer. Lancet. 2:1988;990-992.
79. Wotherspoon H A, Anderson J R, Morran C G, Murray G D, McArdle C S. Randomized controlled trial of an H2-receptor antagonist in gastric cancer. Br J Surg. 84:1997;1168-1169.
80. Brunda M J, Bellantoni D, Sulich V. In vivo anti-tumoral activity of combinations of interferon alpha and interleukin-2 in a murine model. Correlation of efficacy with the induction of cytotoxic cells resembling natural killer cells. Int J Cancer. 40:1987;365-371.
81. Hellstrand K, Hermodsson S, Brune M, Naredi P, Carneskog J, Mellqvist U H. Histamine in cancer immunotherapy. Scand J Clin Lab Invest. 57:1997;193-202.
82. Johansson S, Landstrom M, Hellstrand K, Henriksson R. The response of Dunning R3327 prostatic adenocarcinoma to IL-2, histamine and radiation. Br J Cancer. 77:1998;1213-1219.
83. Johansson S, Landstrom M, Henriksson R. Alterations of tumour cells, stroma and apoptosis in rat prostatic adenocarcinoma following treatment with histamine, interleukin-2 and irradiation. Anticancer Res. 19:1999;1961-1969.
84. Johansson M, Bergheim A, Henriksson R. Histamine and Interleukin-2 inhibit growth and neovascularisation in malignant glioma. J Neurooncol. 39:1998;abstr. P-125.
85. Hellstrand K, Naredi P, Lindner P, Lundholm K, Rudenstam C M, Hermodsson S, Asztely M, Hafstrom L. Histamine in immunotherapy of advanced melanoma: a pilot study. Cancer Immunol Immunother. 39:1994;416-419.
86. Barth A, Wanek L A, Morton D L. Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg. 181:1995;193-201.
87. Bar M H, Sznol M, Atkins M B, Ciobanu N, Micetich K C, Boldt D H, Margolin K A, Aronson F R, Rayner A A, Hawkins M J et al. Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cells. J Clin Oncol. 8:1990;1138-1147.
88. Hellstrand K, Mellqvist U H, Wallhult E, Carneskog J, Kimby E, Celsing F, Brune M. Histamine and interleukin-2 in acute myelogenous leukemia. Leukemia Lymphoma. 27:1997;429-438.
89. Blaise D, Olive D, Michallet M, Marit G, Leblond V, Maraninchi D. Impairment of leukaemia-free survival by addition of interleukin-2-receptor antibody to standard graft-versus-host prophylaxis. Lancet. 345:1995;1144-1146.
90. Meloni G, Vignetti M, Pogliani E, Invernizzi R, Allione B, Mirto S, Sica S, Leoni F, Selleri C, Mandelli F. Interleukin-2 therapy in relapsed acute myelogenous leukemia. Cancer J Sci Am 3 Suppl. 1:1997;S43-47.
91. Hakansson L. Therapeutic strategies in metastatic renal cell carcinoma - an overview. Rev Series Oncol. 2:1998;2-9.
92. Whiteside T L, Vujanovic N L, Herberman R B. Natural killer cells and tumor therapy. Curr Top Microbiol Immunol. 230:1998;221-244.
93. Rubin J T, Elwood L J, Rosenberg S A, Lotze M T. Immunohistochemical correlates of response to recombinant interleukin-2-based immunotherapy in humans. Cancer Res. 49:1989;7086-7092.
94. Sznol M, Parkinson D R. Clinical applications of IL-2. Oncology (Huntingt). 8:1994;61-75.
95. Belldegrun A, Tso C L, Kaboo R, Pang S, Pierce W, deKernion J B, Figlin R. Natural immune reactivity-associated therapeutic response in patients with metastatic renal cell carcinoma receiving tumor-infiltrating lymphocytes and interleukin-2-based therapy. J Immunother Emphasis Tumor Immunol. 19:1996;149-161.
96. Gohring B, Riemann D, Rebmann U, Heynemann H, Schabel J, Langner J. Prognostic value of the immunomonitoring of patients with renal cell carcinoma under therapy with IL-2/IFN-alpha-2 in combination with 5-FU. Urol Res. 24:1996;297-303.
97. Wersall P, Mellstedt H. Increased LAK and T cell activation in responding renal cell carcinoma patients after low dose cyclophosphamide, IL-2 and alpha-IFN. Med Oncol. 12:1995;69-77.
98. Mitchell M S. Chemotherapy in combination with biomodulation: a 5-year experience with cyclophosphamide and interleukin-2. Semin Oncol. 19:1992;80-87.
99. Hakansson A, Gustafsson B, Krysander L, Hakansson L. Tumour-infiltrating lymphocytes in metastatic malignant melanoma and response to interferon alpha treatment. Br J Cancer. 74:1996;670-676.
100. van Bezooijen R L, Goey H, Stoter G, Hermans J, Fleuren G J. Prognostic markers for survival in patients with metastatic renal cell carcinoma treated with interleukin-2. Cancer Immunol Immunother. 43:1996;293-298.
101. Lissoni P, Barni S, Ardizzoia A, Scardino E, Tancini G, Vigano M G. Correlation between pretreatment serum levels of neopterin and response to interleukin-2 immunotherapy in cancer patients. J Biol Regul Homeost Agents. 9:1995;21-23.
102. Hellstrand K, Brune M, Mellqvist U H, Naredi P. Histamine, cimetidine and colorectal cancer [Letter]. Nat Med. 2:1996;364-365.
103. Falus A, Meretey K. Histamine: an early messenger in inflammatory and immune reactions. Immunol Today. 13:1992;154-156.
104. Wallhult E, Mellqvist U H, Celsing F, Hellstrand K, Nilsson B, Simonsson B, Brune M. Safety and feasibility of IL-2 plus histamine dihydrochloride (Maxamine (TM)) in AML patients in first or subsequent complete remission. Blood. 92:1998;614A.
105. Sjoberg J, Andersson M, Björkholm M, Brune M, Hellstrand K, Pisa P. Immunotherapy with IL-2 and histamine upregulates downmodulated T cell and NK cell-associated zeta expression in acute myeloid leukemia (AML). Haematolgica. 84:1999;10.